Xarelto Lawsuit News: Xarelto Trial Results Questioned Due To Defective Device

December 10, 2015 – – BloodThinnerHelp.com details reports from Reuters on the latest news surrounding blood-thinner Xarelto. At this time, it has been learned that both United States and European drug regulators are researching whether a defective blood clotting test device may have affected the outcome of trial results involving Xarelto manufactured by Bayer AG.

Xarelto is now the subject of over 2,000 lawsuits which commonly allege that the blood thinner causes significantly dangerous uncontrollable bleeding episodes in patients. The lawsuits surrounding the drug which were filed federally have been consolidated to form multidistrict litigation number 2592 in the Eastern District of Louisiana.

The new study was planned in order to compare Xarelto with a more traditional blood thinner (warfarin) in overall effectiveness for preventing strokes in patients with atrial fibrillation, (a common irregular heartbeat condition in older individuals). During the study, however, results may have been affected because of a defect in the medical device used.

“Due to the defect, it is now thought that the INR (international normalized ration) device may have impacted the clotting results in some patients in the warfarin group,” the European Medicines Agency stated after the study. They noted that they would publish the study’s results after their investigation into the effects of the defective device were completed.

INR devices measure how fast blood begins to clot. It has been said that the system used for this study was recalled in December of 2014 due to the discovery of some falsely low results.

Plaintiffs involved in Xarelto lawsuits have alleged that Xarelto is currently the most dangerous blood thinner on the market due to the fact that it has no corresponding antidote. If someone using Xarelto becomes injured and bleeds, doctors will be unable to get that person’s blood to clot, and will have to resort to extreme life-saving measures such as surgery or blood transfusions in order to try to save the person’s life.

Individuals taking traditional blood thinners do not have this issue, due to the fact that traditional blood thinners have an available antidote in vitamin K. When these patients begin to bleed, doctors can treat them with vitamin K, which will counter the effects of the drug and allow their blood to clot.

As the cases involved in the Xarelto MDL and Xarelto mass tort grouping await trial, Attorney Joseph Osborne is working to help ensure that everyone who has been negatively affected by Xarelto will be able to explore their legal rights. Anyone who took Xarelto and subsequently suffered from adverse health events may be entitled to compensation. Attorney Osborne is offering free consultations to these individuals.

To request more information regarding Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60006202